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1. Introduction
Cancer is one of the most severe health problems in both developing and developed countries,
worldwide. Among the most common (lung, stomach, colorectal, liver, breast) types of cancers,
lung cancer has continued to be the most common cancer diagnosed in men and breast cancer
is the most common cancer diagnosed in women. An estimated 12.7 million people were
diagnosed with cancer across the world in 2008, and 7.6 million people died from the cancer
during the same year [1]. Lung cancer, breast cancer, colorectal cancer and stomach cancer
accounted for two-fifths of the total cases of cancers diagnosed worldwide [1]. More than 70%
of all cancer deaths occurred in low- and middle-income countries. Deaths due to cancer are
projected to continuously increase and it has been estimated that there will be 11.5 million
deaths in the year 2030 [1] and 27 million new cancer cases and 17.5 million cancer deaths are
projected to occur in the world by 2050 [2]. According to Canadian cancer statistics, issued by
the Canadian Cancer Society, it is estimated that 186,400 new cases of cancer (excluding 81,300
non-melanoma skin cancers) and 75,700 deaths from cancer will occur in Canada in 2012 [1].
The lowest number of incidences and mortality rate is recorded in British Columbia. Both
incidence and mortality rates are higher in Atlantic Canada and Quebec [3].
More than 30% of cancers are caused by modifiable behavioral and environmental risk factors,
including tobacco and alcohol use, dietary factors, insufficient regular consumption of fruit
and vegetable, overweight and obesity, physical inactivity, chronic infections from Helicobacter
pylori, hepatitis B virus (HBV), hepatitis C virus (HCV) and some types of human papilloma
virus (HPV), environmental and occupational risks including exposure to ionizing and non-
ionizing radiation [4].
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Conventional treatment of cancer includes interventions such as psychosocial support,
surgery, radiotherapy and chemotherapy [4]. Currently, the most commonly use cancer
chemotherapy includes mainly alkylating agents, antimetabolites, antitumor antibiotics,
platinum analogs and natural anticancer agents. However, due to the increasing rate of
mortality associated with cancer and adverse or toxic side effects of cancer chemotherapy and
radiation therapy, discovery of new anticancer agents derived from nature, especially plants,
is currently under investigation. Screening of medicinal plants as a source of anticancer agents
was started in the 1950s, with the discovery and development of vinca alkaloids, vinblastine
and vincristine and the isolation of the cytotoxic podophyllotoxins [5] (Figure 01). The cool
temperate climate of North America supports the growth of an enormous number of plant
species which are important sources of unique phytochemicals having anticancer properties
(Table 01). In this chapter, selected medicinal plants grown in the cool climate of North America
(mainly Canada and USA) are discussed. The major bioactive phytochemicals and their
mechanisms of action are also reviewed.
     
 
 
 
  
 
 
 
 
 
 
         (a) Vinblastine                            (b) Vincristine                                (c) Podophyllotoxins 
Metabolite Natural source Mode of action Ref 
Botanical name Family 
Vinblastine  Catharanthus roseus 
(Madagascar periwinkle) 
Apocenacea  Inhibition of microtubule 
assembly  
6, 7 
Vincristine  Catharanthus roseus 
(Madagascar periwinkle) 
Apocenacea Inhibition of microtubule 
assembly  
6, 7 
Podophyllotoxins Podophyllum hexandrum 
(Himalayan mayapple) 
Berberidaceae Inhibition of microtubule 
assembly 
8, 9 
 
   (a) Vinblastine – [dimethyl (2β,3β,4β,5α,12β,19α)- 15-[(5S,9S)- 5-ethyl- 5-hydroxy- 9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro- 2H- 3,7-methanoazacycloundecino[5,4-b]indol- 9-yl] - 3-hydroxy- 16-methoxy- 1-methyl-
6,7-didehydroaspidospermidine- 3,4-dicarboxylate] (b) Vincristin – [(3aR,3a1R,4R,5S,5aR,10bR)-methyl 4-acetoxy-3a-
ethyl-9-((5S,7S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-2,4,5,6,7,8,9,10-octahydro-1H-3,7-
methano[1]azacycloundecino[5,4-b]indol-9-yl)-6-formyl-5-hydroxy-8-methoxy-3a,3a1,4,5,5a,6,11,12-octahydro-1H-
indolizino[8,1-cd]carbazole-5-carboxylate] (c) Podophyllotoxin – [(10R,11R,15R,16R)-16-hydroxy-10-(3,4,5-
trimethoxyphenyl)-4,6,13-trioxatetracyclohexadeca-1,3(7),8-trien-12-one]
Figure 1. Some selected currently used phytochemical-based anticancer agents
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Plant Family Partsused Major bioactive compounds
Growing
regions Ref
Achyranthes
aspera
(Devil’s Horsewhip)
Amaranthaceae Leaf Triterpenoid saponins USA 14
Annona glabra
(Pond apple)
Annonaceae Leaf and
fruit
Acetogenins USA 15
Aralia nudicaulis
(Wild sarsaparilla)
Araliacea Whole
plant
Steroids, sarsasapogenin, smilagenin,
sitosterol, stigmasterol, pollinastrenol,
glycosides, saponins, sarsasaponin
parillin, smilasaponin, smilacin,
sarsaparilloside, and sitosterol
glucoside
Mainly
Canada
16
Aster brachyactis
(Rayless aster)
Asteraceae Aerial
parts
Not known North
America
17
Carduus nutans
(Nodding
plumeless thistle)
Asteraceae Aerial
parts
Linalool derivatives, aliphatic acids,
diacids, aromatic acids, and phenols
North
America
18, 19
Erythronium
americanum
(Adder’s tongue)
Liliaceae Whole
plant
Alpha-methylenebutyrolactone North
America
20, 21
Eupatorium
cannabinum
(Bonesets)
Asteraceae Whole
plant
Sesquiterpene lactone, pyrrolizidine
alkaloid, and flavonoid
North
America
20, 21,19,
22
Foeniculum
vulgare
(Wild pepper
fennel)
Apiaceae Seed α-pinene, anisic aldehyde, cineole,
fecchone, limonene, and myrcene
North
America
23
Hydrastis
canadensis
(Orange root)
Ranunculaceae Whole
plant
Isoquinoline alkaloids (hydrastine,
berberine, berberastine, candaline),
resin and lactone
Canada, USA 20, 21
Hypericum
perforatum
(St. John’s wort)
Clusiaceae Flower Hypericin and hyperforin USA, Canada
(British
Columbia)
24
Lactuca sativa
(Garden lettuce)
Asteraceae Leaf Sesquiterpene lactone USA, Canada 25
Lantana camara
(Wild sage)
Verbenaceae Whole
plant
Alkaloids (camerine, isocamerine,
micranine, lantanine, lantadene),
phenols, flavonoids, tannins, saponins,
and phytosterols
USA 26, 27, 28
Larrea tridentate
(Creosote bush)
Zygophyllaceae Whole
plant
Resins and lignans Southwester
n USA
18, 29, 30
Linum
usitatissimum
(Common Flax)
Linaceae Seed Enterodiol, enterolactone, lignans, and
omega-3 fatty acids
Canada, USA 31, 32
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Plant Family Partsused Major bioactive compounds
Growing
regions Ref
Olea europrae
(Olive)
Oleaceae Leaf and
oil
Oleuropein, hydroxytyrosol,
hydroxytyrosol acetate, luteolin-7-O-
glucoside, luteolin-4’-O-glucoside and
luteolin, oleic acid and polyphenol
USA 33, 34,
35, 36, 37
Panax
quinquefolius
(North American
Ginseng)
Araliaceae Root,
Leaf
Ginsenosides and saponins Eastern North
America
20, 21
Plantago
lanceolata
(Ribwort plantain)
Plantaginaceae Aerial
parts
Phenolics and flavonoids Canada, USA 38
Podophyllum
peltatum
(Mayapple)
Berberidaceae Rhizome Podophyllotoxins Eastern North
America
39
Polygonatum
multiflorum
(Tuber fleece
flower)
Polygonaceae Whole
plant
Saponin and flavonoid and vitamin A USA 20, 21, 40
Pyrus malus
(Apple)
Rosaceae Bark and
fruit
Quercetin, catechin, flavonoid,
coumaric and gallic acids, phloridzin
and procyanidin
North
America
21
Rhodiola rosea
(Golden root)
Crassulaceae Rhizome Monoterpene alcohols and their
glycosides, cyanogenic glycosides, aryl
glycosides, phenylethanoids,
phenylpropanoids and their
glycosides, flavonoids, flavonlignans,
proanthocyanidins and gallic acid
derivatives
Eastern
Canada
41, 42
Saponaria vaccaria
(Cowherb)
Caryophyllaceae Seed Flavonoids, cyclopeptides, and
bisdesmosidic saponins
Western
Canada
43
Silybum marianum
(Milk thistle)
Asteraceae Dried
fruit,
seed
Silymarin-polyphenoic flavolignans
(silybin, isosilybin, silychristin,
silydianin and taxifoline)
Canada, USA 44, 45
Sonchus arvensis
(Perennial sow-
thistle)
Asteraceae Whole
plant
Alkanes, n-alkenes, n-aldehydes and n-
alcohols, shikimate metabolites,
carotenoid-derived compounds,
terpenoids, steroids, and phenols
Canada 46, 47
Tanacetum vulgare
(Tansy)
Asteraceae Aerial
parts
Monoterpenes, sesqueterpenes, and
oxygenated sesqueterpenes
Canada, USA 48
Taraxacum
officinale
(Dandelions)
Asteraceae Root and
leaf
Sesquiterpene lactones, triterpenoids,
sterols, tannins, alkaloids, inulin,
caffeic acid, and flavonoids
North
America
49
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Plant Family Partsused Major bioactive compounds
Growing
regions Ref
Taxus brevifolia
(Pacific yew tree)
Taxaceae Bark Taxol (diterpene) Pacific
Northwest
50
Thuja occidentalis
(White cedar)
Cupressaceae Whole
plant
Flavonoid, tannin, and volatile oil Northeastern
USA,
Eastern
Canada
13, 51
Xanthium
strumarium
(Cocklebur)
Asteraceae Fruit Sesquiterpene lactones (Xanthatin
and Xanthinosin)
Canada 17
Table 1. Medicinal plants with potential anticancer properties grown in North America
2. Pathophysiology of cancer
Cancer is a population of abnormal cells which divide without control, with the ability to
invade other tissues. Cancer and some of the other chronic diseases share common pathogen‐
esis mechanisms, such as DNA damage, oxidative stress, and chronic inflammation [10]. It is
understood that both environmental factors and chemical carcinogens play a key role in the
initiation and progression of cancer. Among the major environmental factors are asbestos,
polluted air near industrial emission sources, exposure to secondary tobacco smoke, indoor
air pollution such as radon, drinking water containing arsenic, chlorination by-products, and
other pollutants [11]. Chemicals with carcinogenic activity can be classified as DNA reactive
(e.g.: nitrogen mustards, chlorambucil, epoxides, aliphatic halides, aromatic amines), epige‐
netic (e.g.: chlordane, pentachlorophenol, hormones, cyclosporin, purine analogs), dichloro‐
diphenyltrichloroethane, phenobarbital, minerals (e.g.: asbestos), metals (e.g.: arsenic,
beryllium, cadmium) and unclassified carcinogens (e.g.: acrylamide, acrylonitrile, dioxane)
[12]. DNA-reactive carcinogens act in the target cells of tissue(s) of their carcinogenicity to form
DNA adducts that are the basis for neoplastic transformation [12]. Epigenetic carcinogens lack
chemical reactivity and hence, do not form DNA adducts. These carcinogens are produced in
the target cells of tissue(s) of their carcinogenicity. Effects of epigenetic carcinogens indirectly
lead to neoplastic transformation or enhance the development of tumors from cryptogenically
transformed cells [12].
Carcinogenesis is a multi-step process consisting of tumor initiation, promotion and progres‐
sion [13]. Cancer initiation can be blocked by activating protective mechanisms, either in the
extracellular environment or intracellular environment by modifying trans-membrane
transport, modulating metabolism, blocking reactive oxygen and nitrogen species, maintain‐
ing DNA structure, modulating DNA metabolism and repair, and controlling gene expression
[10]. Tumor promotion is the second stage of carcinogenesis and is followed by tumor
progression. Both stages can be suppressed by inhibiting genotoxic effects, favoring antioxi‐
dant and anti-inflammatory activity, inhibiting proteases and cell proliferation, inducing cell
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differentiation, modulating apoptosis and signal transduction pathways and protecting
intercellular communications [10]. In addition, tumor progression can also be inhibited by
affecting the hormonal status and the immune system in various ways and by inhibiting tumor
angiogenesis [10].
3. In vitro anticancer activity of phytochemicals and extracts of medicinal
plants
Cultured cancer-derived cell lines with comparison to normal healthy cell lines are commonly
used to assess the anticancer properties of isolated phytochemicals and extracts of medicinal
plants (Table 2). The anticancer properties of ethanolic extract of leaves, pulp and seeds of,
Annona glabra (L.), commonly known as pond apple, were shown, using human drug-sensitive
leukemia (CEM) and its multidrug-resistant-derived (CEM/VLB) cell lines [52]. The most
potent anticancer activity was shown in the seed extract of A. glabra [52]. Both dried rhizome
hexane extract and dried fruit hexane extract, partitioned from total methanol extract, of Aralia
nudicaulis (L.) caused death of cancer cell lines such as human colon cancer cell (WiDr), human
leukemia cell (Molt) and human cervix cancer cell (HeLa) at a lower concentration, than that
of required for the death of normal cells [53]. Eupatoriopicrin, a sesquiterpene lactone isolated
from Eupatorium cannabinum (L.) (Bonesets), indicated anticancer properties on FIO 26
(fibrosarcoma) cells with an IC50=1.5 µg/ml [22]. Methanolic extracts of Hypericum perforatum
(L.) (St. Johns wort) possessed strong antiproliferative activity in the human prostate cell line
(PC-3) and the major constituents, hyperforin and hypericin, synergistically contributed to the
reduction of the PC-3 cells proliferation [24]. Maslinic acid, (Figure 2(a)) a triterpene from Olea
europaea (L.) (Olive), has shown to be significantly inhibitory in cell proliferation of the human
colorectal adenocarcinoma cell line (HT29) in a dose dependent manner [33]. The major
components in the extract were identified to be oleuropein, hydroxytyrosol, hydroxytyrosol
acetate, luteolin-7-O-glucoside, luteolin-4’-O-glucoside and luteolin [34] (Figure 2). All these
phytochemicals inhibited the proliferation of cancer and endothelial cells with IC50, at the low
micromolar range [37]. Methanolic leaf extract of Plantago lanceolata (L.) (Ribwort plantain)
inhibited the growth of three different cell lines; human renal adenocarcinoma (TK-10), the
human breast adenocarcinoma (MCF-7) and the human melanoma (UACC-62) cell lines and
the MCF-7 was totally inhibited [54]. Further, the ethanolic extract of P. lanceolata (L.), produced
by maceration with ethanol : water, showed significant antiproliferative activity on cervix
epithelioid carcinoma (HeLa), breast adenocarcinoma (MCF-7), colon adenocarcinoma
(HT-29) and human fetal lung carcinoma (MRC-5) [38]. Several chemical constituents (Figure
3) from Silybum marianum (Milkthistle) have been isolated and their cytotoxic and anticancer
potential has been investigated, in vitro, using both cancer and normal healthy cell lines.
Silymarin, isolated from seeds of S. marianum, is a mixture of series of flavolignans, major
constituents being: silybin A and B, (also known as silibinin), isosilybin A and B, silychristin,
and silydianin [55, 56].
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 (a) Maslinic acid      
IC50 
(μg/ml) 
MOA Ref 
28.8  Bcl-2 
inhibition 
Bax 
activation 
33 
                                                                       
  (d) Oleuropein      (e) Luteolin-4’-O-glucoside 
IC50(μg/ml) 
MOA Ref 
BBCE T24 MCF-7 
2.6 7.6 12.0 Induce G1 cell cycle arrest 35, 37 
                                    
   (f) Luteolin-7-O-glucoside      (g) Luteolin 
IC50 (μg/ml) 
MOA Ref 
BBCE T24 MCF-7 
3.9 11.4 40.9 Inhibition of 
Topoisomerase - 1 
37, 55 
 
 IC50 (μg/ml) 
MOA Ref 
BBCE T24 MCF-7 
30.9 31.7 10.8 - 37 
 
                            
 (b) Hydroxytyrosol                       (c) Hydroxytyrosol acetate 
 IC50 (μg/ml) 
MOA Ref 
BBCE T24 MCF-7 
9.7 28.2 9.1 Inhibition of 
Topoisomerase - 1 
37, 55 
 
 Metabolite 
IC50 (μg/ml) 
MOA Ref 
BBCE T24 MCF-7 HL60 HT29 
Hydroxytyrosol 2.4 12.4 24.9 50.0 750.0 
Cell cycle arrest at 
G0/ G1 
34,35,5
3 
Hydroxytyrosol 
acetate 
9.3 23.3 28.7 - -  34 
 
IC50: Concentration which inhibited 50% of cell proliferation; MOA: Mode of Action; BBCE: Bovine Brain Capillary En‐
dothelial cells; T24: Human Urinary Bladder Carcinoma cells; MCF-7: Human Breast Adenocarcinoma cells; HL60: Hu‐
man Promyelocytic Leukaemia cells; HT29: Colon Adenocarcinoma cells
(a) Maslinic acid - [(2a, 3b)-2,3-dihydroxyolean-12-en-28-oic acid]: (b) Oleuropein – [(4S,5E,6S)-4-[2-[2-(3,4-dihydroxy‐
phenyl)ethoxy]-2-oxoethyl]- 5-ethylidene-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)- 2-tetrahydropyran‐
yl]oxy]-4H-pyran-3-carboxylic acid, methyl ester] : (c) Hydroxytyrosol – [4-(2-Hydroxyethyl)-1,2-benzenediol]: (d)
Hydroxytyrosol acetate – [2-(3,4-dihydroxy)Phenyl ethyl acetate;4-[2-(Acetyloxy)ethyl]-1,2-benzenediol]: (e) Luteolin-
7-O-glucoside - [2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl beta-D-glucopyranoside; 4H-1-benzopyr‐
an-4-one, 2-(3,4-dihydroxyphenyl)-7-(beta-D-glucopyranosyloxy)-5-hydroxy-; 2-(3,4-Dihydroxy-phenyl)-5-hydroxy-7-
((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chromen-4-one] (f) Luteolin-4’-O-
glucoside – [3',5,7-Trihydroxy-4'-(β-D-glucopyranosyloxy)flavone;2-(4-β-D-Glucopyranosyloxy-3-hydroxyphenyl)-5,7-
dihydroxy-4H-1-benzopyran-4-one;2-[3-Hydroxy-4-(β-D-glucopyranosyloxy)phenyl]-5,7-dihydroxy-4H-1-
benzopyran-4-one] (g) Luteolin - [2-(3,4-Dihydroxyphenyl)- 5,7-dihydroxy-4-chromenone]
Figure 2. Major bio-active compounds present in Olea europaea (a,b,c,d,e,f and g) and Plantago lanceolata (f and g)
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Silybin possessed a dose-dependent growth inhibitory effect on parental ovarian cancer cells
(OVCA 433), drug-resistant ovarian cancer cells (A2780 WT) and doxorubicin (DOX)-resistant
breast cancer cells (MCF-7) [55]. Both L and D diastereoisomers of silybin inhibited A2780 WT
cell growth at low IC50 reported with L-diastereoisomer [55]. Furthermore, silybin potentiatedthe effect  of  Cisplatin  (CDDP,  a  platinum analog;  cis-diamminedichloroplatinum [II])  in
inhibiting A2780 WT and CDDP-resistant cell growth. Cisplatin is an inorganic metal com‐
plex which acts as an alkylating agent [57]. Similar results recorded with doxorubicin (DOX) on
MCF-7 DOX-resistant cells when silybin associated with doxorubicin. Doxorubicin ((7S,9S)-7-
[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyace
tyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione) is an anthracycline antibiotic isolated
from Streptomyces  peucetius  var  caesius  [57].  The effect  of  silybin-CDDP and silybin-DOX
combinations resulted in a synergistic action, as assessed by the Berembaum isobole method
[55]. Silymarin demonstrated to have marked inhibition of cell proliferation with almost 50%
inhibition in a time dependent manner on the human breast cancer cell line (MDA-MB 468), at
25 µg/mI concentration, after five days of treatment. Its potential anticancer activity was dose
dependent and showed a complete inhibition of cancer cells at 50 and 75 µg/mI concentra‐
tions at the beginning of Day 2 of exposure [56]. Induction of apoptotic cell death of human
prostate cancer (DU145) treated with silibinin is shown to be due to activation of caspase 9 and
caspase 3 enzymes [58].
4. Evidence from animal studies for anticancer activity of North American
medicinal plants
Anticancer and antiproliferative potential of some North American medicinal plants has also
been studied in animal studies (Table 3). In vivo antitumor activities of Achyranthes aspera (L.)
(Devil’s Horsewhip) on athymic mice, with are subcutaneous xenograft, harboring human
pancreatic tumor were demonstrated, using the leaf extract. The leaf extract significantly reduced
both tumor weight and volume in mice treated with leaf extract intraperitonealy [14]. Intrave‐
nous administration of 40 mg/kg body weight eupatoriopicrin, a sesquiterpene lactone present
in E. cannabinum, significantly delayed the growth of tumor in Lewis lung tumour-bearing
syngeneic C57B1 female mice [22]. A 70% inhibition of tumor growth in PC-3 cells, orthopedi‐
cally implanted into the dorsal prostatic lobe in athymic nude mice, was observed, upon their
receiving 15 mg/kg intraperitoneal H. perforatum methanolic extract [24]. Lantadene A is a
pentacyclic triterpenoid, isolated from the weed, Lantana camara (L) [59]. Feeding of female Swiss
albino mice (LACCA) with a dose of 50 mg/kg body weight of Lantadene A twice a week for 20
weeks, showed potential chemopreventive activity. This chemopreventive activity could be
linked to the expression of transcriptional factors and a significant decrease in the mRNA
expression of AP-1 and c-fos), NF-kB (p-65) and p53 was observed in Lantadene A treated mice
skin tumors [59]. Silibinin decreased tumor multiplicity by 71% (P < 0.01) in wild type mice, but
did not show any such considerable effect in iNOS-/- mice upon oral feeding of 742 mg/kg body
weight silibinin for 5 days per week for 18 weeks [60]. Lesser effects of silibinin in iNOS-/- mice
suggested that most of its chemopreventive and angiopreventive effects were through its
inhibition of iNOS expression in lung tumors [60]. Treatment of a purified diet, containing 0.5%
to 1.0% silibinin on a transgenic adenocarcinoma of are mouse prostate (TRAMP) model,
Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century166
decreased the weight of the tumor in both the prostate and seminal vesicle, when compared
with control mice [61].
Treatment of silibinin significantly decreased tumor angiogenesis and proliferation and also
there was increased apoptosis in prostate tumor tissue samples in the TRAMP model [61]. The
protective effect of silibinin was also demonstrated in mouse skin with tumors caused by acute
and chronic UVB-exposure-caused mitogenic and survival signaling and associated biological
responses [62]. Mice were treated with silibinin, either topically (9 mg in 200 ml acetone/mouse)
or orally (1% of diet), and both administrations strongly inhibited UVB-induced skin tumori‐
genesis in a long-term study [62]. Thymine dimers are formed in DNA, immediately after UVB
irradiation, and are considered as an early and important biomarker for UVB induced DNA
damage [62]. A noticeable, 71% reduction (P < 0.001) of thymine positive cells was obtained in
the mice treated with 1% (w/w) silibinin before the UVB exposure, compared with the UVB
alone group [62]. Oral feeding of 200 mg/kg of silibinin for 5 days per week, for 33 days,
significantly inhibited human non–small-cell lung cancer cells (NSCLC A549) tumor xenograft
growth in nude mice, in a time-dependent manner [63]. This accounted for 58% (P = 0.003)
reduction in tumor weight per mouse and intraperitoneal administration of 4 mg/kg doxoru‐
bicin, once a week for four weeks, showed 61% (P = 0.005) reduction in tumor weight. However,
interestingly, in silibinin-doxorubicin combination, 76% (P = 0.002, versus control) decrease in
tumor weight per mouse was observed, that which was significantly different from either
treatment alone, showing enhanced efficacy [63].
5. Mode of action of selected phytochemicals of North American medicinal
plants
Apoptosis (programmed cell death) is the principal mechanism through which unwanted or
damaged cells are safely eliminated from the body. This programmed cell death is mediated
via either an extrinsic apoptotic pathway or an intrinsic apoptotic pathway [65]. These two
apoptosis signaling pathways differ in the origin of their apoptosis signal, but converge upon
a common pathway [66].
The extrinsic pathway is initiated by the stimulation of the cell surface ‘death receptor’ due to
the binding of death ligand and the intrinsic pathway is also known as the mitochondrial
pathway in which an intracellular apoptotic signal initiates the process [68]. Various natural
extracts, obtained from medicinal plants grown in North America, have been found to induce
apoptosis pathways at different levels (Figure 4 and Table 04). Leaf extract of Achyranthes
aspera activated caspase-3 and induced caspase-3 mRNA in tumor cells. It also decreased Akt-1
transcription, as well its phosphorylation. Suppression of pAkt-1 and a corresponding
activation of caspase 3 by the leaf extract, induced apoptosis of tumor cells [14]. It was also
found that maslinic acid, isolated from O. europaea, inhibited considerably the expression of
Bcl-2 (B-cell lymphoma 2), whilst increasing that of Bax. Maslinic acid stimulated the release
of mitochondrial cytochrome-c and activated caspase-9 and caspase-3 [33]. These results
showed the activation of the mitochondrial apoptotic pathway, in response to the treatment
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(a) Silybin A      (b) Silybin B 
Metabolite 
IC50(µg/ml) 
MOA Ref 
MCF7 OVCA 433 A2780 
Silybin 4.8-24 14(L) 
20(D) 
25 Induce G1 arrest  
Inhibits STAT3 activation  
Up-regulates DNA-Protein Kinase-
dependent p53 Activation 
56  
58 
 
67 
 
                        
(c) Isosilybin A      (d) Isosilybin B 
Metabolite IC50(µg/ml)
a
 / Apoptosis induction
b
 MOA Ref 
22Rv1  LAPC4 LNCaP DU 145 
Isosilybin A 
 
Isosilybin B 
90-180
b
 
 
- 
90-180
b
 
 
- 
90-180
b
 
 
- 
32
a
 
20.5
a
 
Activates Akt–NF-kB–AR axis and increases p53 level 
 
Increases p53 level 
68, 69 
 
69 
                          
(e) Silychristin      (f) Silydianin 
 
IC50: Concentration which inhibited 50% of cell proliferation; MOA: Mode of Action; MCF-7: Doxorubicin-resistant
breast cancer cells; OVCA 433: Parental ovarian cancer cells; A2780: Drug-resistant ovarian cancer cells; 22Rv1,
LAPC4, LNCaP, DU 145: Human prostate cancer cells
(a) Silybin A – [(2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydroben‐
zo[b] [1,4]dioxin-6-yl]chroman-4-one]: (b) Silybin B – [(2R,3R)-3,5,7-trihydroxy-2-[(2S,3S)-3-(4-hydroxy-3-methoxy‐
phenyl)-2-(hydroxymethyl)-2,3-dihydrobenzo[b] [1,4]dioxin-6-yl]chroman-4-one]: (c) Isosilybin A –[(2R,3R)-3,5,7-
Trihydroxy-2-[(2R,3R)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydrobenzo[1,4]dioxin-6-yl]-4-
chromanone]: (d) (c) Isosilybin B –[(2R,3R)-3,5,7-Trihydroxy-2-[(2R,3R)-2-(4-hydroxy-3-methoxyphenyl)-3-
(hydroxymethyl)-2,3-dihydrobenzo[1,4]dioxin-6-yl]-4-chromanone]: (e) Silychristin – [(2R,3R)-3,5,7-trihydroxy-2-[(2R,
3S)-7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1-benzofuran-5-yl]-2,3-dihydrochro‐
men-4-one]:
Figure 3. Major bio-active flavonolignans present in Silybum marianum
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of HT29 colon-cancer cells with maslinic acid. The major flavonoid present in P. lanceolata,
luteolin-7-O-β-glucoside, as well as aglycon luteolin, acted as potent poisons for DNA
topoisomerase I on cancer cell lines [54]. Silibinin (major bioactive component from S. maria‐
num) markedly activated the DNA-PK-p53 pathway for apoptosis, in response to UVB-
induced DNA damage [69]. DNA-PK pull-down assay showed that silibinin pre-treatment
strongly increased binding of DNA protein kinase with p53 [69].
Plant Extraction
solvent and
concentration
Type of cancer
cell line
IC50 or growth
reduction
Key findings Ref
.
Annona glabra
(Pond apple)
Ethanolic
extract of
lyophilized plant
material in
powder form
Human drug-
sensitive leukemia
(CEM) and its
multidrug-
resistant-derived
(CEM/VLB) cell
lines
Leaf-1.00 (CEM/
VLB) Pulp-0.65
(CEM/VLB),
Seed-0.10
(CEM/VLB) and
Leaf-0.30 (CEM),
Pulp-0.35 (CEM),
Seed-0.07 (CEM)
µg/ml
IC50 values were significantly
lower than Adriamycin
(Doxorubicin) (CEM=0.13
μg/ml and CEM/VLB=13.4
μg/ml) indicates its potential
for cancer drug discovery
programs
52
Aralia
nudicaulis
(Wild
sarsaparilla)
Methanol
extracts of
rhizome, stem,
leaf and fruit
were further
partitioned with
hexane, ethyl
acetate, butanol
and water
WiDr (colon), Molt
(leukemia), HeLa
(cervix)
Hexane rhizome
extract 30.1
(WiDr), 7.0
(Molt), 33.33
(HeLa) µg/ml
The concentrations of Rhizome
hexane and Fruit hexane
required for normal cell death
was significantly higher than
those required for the cancer
cells
53
Eupatorium
cannabinum
(Bonesets)
Eupatoriopicrin
concentrations
of 0.1 - 50
µg/ml in 96%
ethanol
FIO 26
(Fibrosarcoma)
1.5 µg/ml Possess significant anticancer
activity
22
Foeniculum
vulgare
(Wild pepper
fennel)
Not specified Breast (MCF-7),
liver (HepG2)
- Remarkable anticancer
potential
23
Hypericum
perforatum
(St. John’s wort)
Methanolic
extract
Prostate (PC-3) 0.42 mg/ml Extract components
synergistically contribute to the
24
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Plant Extraction
solvent and
concentration
Type of cancer
cell line
IC50 or growth
reduction
Key findings Ref
.
reduction of the PC-3 cells
proliferation
Linum
Usitatissimum
(Common flax)
Ethanol extract Breast (MCF-7,
MDA-MB-231)
Growth
reduction of
15.8% in MCF-7
and 11.4% in
MDA-MB-231
Significantly reduced cell
growth and induced apoptotic
cell death
31
Olea europrae
(Olive)
maslinic acid 0–
100 µg/mL
Colon (HT29) 28.8 µg/ml Cell proliferation inhibition in a
dose-dependent manner and
causes apoptotic death
33
Aqueous extract
and methanol
artificial mixture
Breast (MCF-7),
Human urinary
bladder (T-24),
Bovine brain
(BBCE)
72 (MCF-7), 100
(T-24), and 62
(BBCE) for aq.
565 (MCF-7),
135 (T-24), and
42 (BBCE) for
methanol µg/ml
Antiproliferative activity of the
extracts should mainly be
attributed to its identified
phytochemicals
34
Plantago
lanceolata
(Ribwort
plantain)
Methanolic
extract
Renal (TK-10),
breast (MCF-7),
melanoma
(UACC-62)
"/>250 (TK-10),
47.2 (MCF-7),
50.6 (UACC-62)
μg/mI
Growth of MCF-7 was totally
inhibited
54
Extracted by
maceration with
ethanol/water
during 72 hr at
room
temperature
cervix epitheloid
(HeLa),breast
(MCF-7), colon
(HT-29), fetal lung
(MRC-5)
172.3 (HeLa),
142.8 (MCF-7),
405.5 (HT-29),
551.7 (MRC-5)
µg/ml
Showed significant
antiproliferative activity
38
Rhodiola rosea
(Golden root)
Not specified Urinary bladder
(RT4, UMUC-3,
T24, 5637, J82)
264 (RT4),100
(UMUC-3), 71
(T24), 151
(5637), 165
(J82) μg/ml
Selectively inhibit the growth of
cancer cell lines with minimal
effect on nonmalignant cells
41
Saponaria
vaccaria
(Cowherb)
70% Methanol
extract
colon (WiDr),
breast (MDA-
MB-231), lung
(NCI-417),
prostate (PC-3),
3.8-9.4 (WiDr),
11.4-19.6 (MDA-
MB-231),
12.6-18.4
Dose-dependent growth
inhibitory and selective
apoptosis-inducing activity.
Strong in a breast and a
prostate cancer cell lines
43
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Plant Extraction
solvent and
concentration
Type of cancer
cell line
IC50 or growth
reduction
Key findings Ref
.
nontumorigenic
fibroblast BJ
(CRL-2522)
(NCI-417)
mg/mI
Silybum
marianum
(Milkthistle)
silybin, a
flavonoid
Doxorubucin
resistant breast
(MCF-7), Parental
ovarian (OVCA
433), Drug-
resistant ovarian
(A2780)
4.8-24 μM
(MCF-7), 14 &
20 μM - L & D
diastereoisomer
s respectively
(A2780)
25 μg/mI
Dose-dependent growth
inhibitory effect on all three cell
lines
55
Silymarin at a
dosages of 10-
75 μg/mI in
ethanol
Breast (MDA-MB
468)
-
-
Inhibits the cell proliferation in
a dose- and time dependent
manner
56
Silibinin in
DMSO
Prostate (DU145) - Strongly inhibited activation of
Stat3 and causes caspase
activation and apoptotic death
58
Isosilybin A and
B
Prostate (LNCaP,
22Rv1)
Prostate (DU 145)
Iso A:32 μM (DU
145)
Iso B:20 μM (DU
145)
Anti-prostate cancer activity
mediated via cell cycle arrest
and apoptosis induction
69
Taraxacum
officinale
(Dandelions)
Water
(lyophilized or
reconstituted)
Acute T-cell
leukemia (Jurkat
clone E6-1),
dominant-
negative FADD
Jurkat cells (clone I
2.1)
- Effectively and selectively
induced apoptosis in human
leukemia cell lines in a dose
and time dependent manner
49
Table 2. Anti-cancer properties of phytochemicals and extracts of medicinal plants revealed from in vitro studies using
cancer cell lines
Plant Preparation Animal model
used
Dosage Key findings Ref.
Achyranthes
aspera
(Devil’s
Horsewhip)
5% suspension in
hexane followed by
extraction in
acetone overnight
Athymic nude
mice
50, 100 and 200
mg/kg extract in
1 ml PBS
administered IP
The tumor weight and
volume was significantly
reduced in the mice treated
for 36 days with 50 mg/kg.
14
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Plant Preparation Animal model
used
Dosage Key findings Ref.
and residue was
dissolved in
methanol
In one treated mouse tumor
completely disappeared
Eupatorium
cannabinum
(Bonesets)
Eupatoriopicrin, a
sesquiterpene
lactone
Syngeneic C57B1
female mice
i.v. injection of 20
or 40 mg/kg
Significantly stronger
growth delay of both lung
tumours and fibrosarcoma
22
Hypericum
perforatum
(Orange
root)
Methanolic extract Human prostatic
carcinoma cell
line
orthotopically
implanted
athymic male
nude mice
ip with a dose of
15 mg/kg
dissolved in 1%
DMSO
Inhibited tumor growth by
70% with no observed side
effects
24
Lantana
camara
(Wild sage)
Lantadene A,
pentacyclic
triterpenoid
Female Swiss
albino mice
(LACCA)
50 mg/kg body
weight twice a
week for 20
weeks
Activity could be linked to
the expression of
transcriptional factors
59
Silybum
marianum
(Milkthistle)
Silibinin Lung - Male
B6/129-
Nos2tm1Lau
(iNOS-/-) and
B6/129PF2 WT
mice
742 mg/kg body
weight for 5
d/wk for 18
weeks
Significantly decreases
urethane-induced tumor
number and size in WT mice.
Decreased tumor
multiplicity in WT mice, but
not in iNOS-/- mice
60
Silibinin Prostate - A
transgenic
adenocarcinoma
of mouse
prostate (TRAMP)
model
Purified diet
containing 0%
and 1%
(w/w) silibinin
until
Decreased the weight of
tumor + prostate + seminal
vesicle. Significantly
decreased tumor
angiogenesis and
proliferation and increased
apoptosis also.
61
Topically applied
silibinin in acetone
or oral feeding of
silibinin
Skin – mouse 9 mg in 200 ml
acetone/mouse
or 1% in diet
silibinin (both topical and
oral) strongly inhibited UVB-
induced skin tumorigenesis
in long-term study
62
Silibinin Skin - SKH-1
hairless mouse
1% (w/w)
silibinin in diet for
2 weeks
Strong suppression of UVB-
induced damage by dietary
feeding of silibinin
63
Silibinin Athymic (BALB/
c,nu/nu) male
nude mice
200 mg/kg body
weight, 5 d/wk
for 33 days
Significantly inhibits human
NSCLC A549 tumor
xenograft growth in a time
dependent manner
64
Table 3. Anti-cancer properties of medicinal plants revealed from in vivo studies using experimental animals
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Figure 4. Schematic representation of current knowledge of mode of action of some selected anticancer phytochemi‐
cals in North America (in a hypothetical cancer cell).
Akt (Protein kinase B); Bcl-2 (Protein kinase B); Bax (Bcl-2–associated X protein); Topo-1
(Topoisomerase 1); p53 (tumor protein 53); Ser15 (Serine 15); NF-kB (nuclear factor kappa-
light-chain-enhancer of activated B cells); AR (Androgen Receptor)
1. Methanolic leaf extract of Achyranthes aspera (MLAa) induces caspase -3 mRNA and
suppress expression of the kinase Akt-1. Apoptosis is induced by activation of caspase-3
and inhibiting Akt-phosphorylation.
2. The mechanism of Maslinic acid (MSA) (isolated from Olea europaea) is regulated via Bcl-2
inhibition and Bax induction, producing mitochondrial disruption, cytochrome-c release,
leading finally to the activation of caspases 9 and caspase 3.
3. Luteolin-7-O-β-glucoside and its aglycon, luteolin (major bio-active constituents of
Plantago lanceolata) showed DNA topoisomerase I poison activities and Topoisomerase
mediated DNA damage might be the possible mechanism which induce apoptosis.
4. Silibinin (SBN) (extracted from Silybum marianum) pretreatment enhance DNA-PK (DNA
Protein kinase) associated kinase activity as well as the physical interaction of p53 with
DNA-PK and it preferentially activates the DNA-PK-p53 pathway for apoptosis.
5. SBN inhibits active Stat3 phosphorylation, and causes caspase activation and apoptosis.
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6. Isosilybin A (ISBN) (extracted from Silybum marianum) activates apoptotic machinery in
human prostate cancer cells via targeting Akt–NF-kB–AR axis.
7. ISBN increases p53 protein levels.
Plant Mode of action References
Achyranthes aspera
(Devil’s Horsewhip)
Significantly induced caspase-3 mRNA and suppressed expression of the pro
survival kinase Akt-1. Apoptosis was induced by activation of caspase-3 and
inhibiting Akt phosphorylation.
14
Olea europaea
(Olive)
Activation of the mitochondrial apoptotic pathway
Significant block of G1 to S phase transition manifested by the increase of cell
number in G0/G1 phase
33
37
Plantago lanceolata
(Ribwort plantain)
The topoisomerase-mediated DNA damage seems to be a candidate
mechanism, by which some flavonoids may exert their cytotoxic potential
54
Silybum marianum
(Milkthistle)
Induces G1 arrest in cell cycle progression
Up-regulates DNA-protein kinase-dependent p53 activation to enhance UVB-
induced apoptosis
Activates apoptotic machinery in human prostate cancer cells via targeting Akt–
NF-kB–AR axis
Inhibits active Stat3 phosphorylation, and causes caspase activation
Increases total p53 levels
56
67
68
58
69
Podophyllum peltatum
(Mayapple)
Inhibition of microtubule assembly 70
Table 4. Mode of action of anticancer activity of phytochemicals present in selected North American medicinal plants
6. Conclusion
Currently, natural products, especially plant secondary metabolites such as isoprenoids,
phenolics and alkaloids, have been demonstrated to be the leading providers of novel
anticancer agents. Thiese important groups of phytochemicals represent a vast majority of
chemical groups, including alkaloids, flavonoids, flavonols, flavanols, terpenes and terpe‐
noids, phenols, flavonolignans and steroids. Potential anticancer properties of these phyto‐
chemicals have been shown by both cell culture (in vitro methods) and animal (in vivo methods)
studies. However, in vitro and in vivo findings should be strengthened by valid human clinical
trial data before introducing to the medicine cabinet as natural therapeutics or drugs.
Abbreviations
CEM, Human drug-sensitive leukemia cells; CEM/VLB, Human multidrug-resistant-derived
leukemia cells; Jurkat clone E6-1, Acute T-cell leukemia cells; WiDr and HT29, Human colon
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cancer cells; Molt, Human leukemia cancer cell; FIO 26, Human fibrosarcoma cells; MCF-7
and MDA-MB-231, Human breast cancer cells; HepG2, Human hepatocarcinoma cells;
LNCaP, 22Rv1, PC-3 and DU145, Human prostate cancer cells; RT4, UMUC-3, T24, 5637 and
J82, Human urinary bladder cancer cells; BBCE, Bovine brain capillary endothelial cells,
TK-10, Human renal cancer cells; UACC-62, Human melanoma cells; HeLa, Human cervical
epithelioid cells; MRC-5, Fetal lung cancer cells; NCI-417, Human lung cancer cells;
CRL-2522, Human nontumorigenic fibroblast cells; OVCA 433, Parental ovarian cancer cells;
A2780, Drug-resistant ovarian cancer cells.
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